Loading…
A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome
The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we descr...
Saved in:
Published in: | ACS chemical biology 2012-10, Vol.7 (10), p.1711 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 10 |
container_start_page | 1711 |
container_title | ACS chemical biology |
container_volume | 7 |
creator | Disney, Matthew D Liu, Biao Yang, Wang-Yong Sellier, Chantal Tran, Tuan Charlet-Berguerand, Nicolas Childs-Disney, Jessica L |
description | The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity. |
doi_str_mv | 10.1021/cb300135h |
format | article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_22948243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22948243</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3</originalsourceid><addsrcrecordid>eNo1j8FKAzEURYMgtlYX_oBk2S5Gk7ykM7MsRatQcKPgrrwkb9qRSWdIUmn_3oK6uptzDlzG7qR4kELJR2dBCAlmd8HG0hhdVDWUI3ad0pcQGuZVfcVGStW6UhrGLCx4Cth1PPQduUNHPO8w84xxSznxOF2uVrMpHYcZx73nbRhi_02Je2rInYF2z5uI2_YsfhaYUu9azOR5jhT6yDHjsUWeTnsf-0A37LLBLtHt307Yx_PT-_KlWL-tXpeLdTFINc-FNs47DaUjbEoyoJpKGgGkfO2l0hKh9PUc0VpTCQJZG0sWrFMSnDLoYcLuf7vDwQbymyG2AeNp8_8bfgAVb1h1</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</creator><creatorcontrib>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</creatorcontrib><description>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</description><identifier>EISSN: 1554-8937</identifier><identifier>DOI: 10.1021/cb300135h</identifier><identifier>PMID: 22948243</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Ataxia - drug therapy ; Binding, Competitive - drug effects ; Cell Nucleus - drug effects ; Cercopithecus aethiops ; COS Cells ; Fragile X Syndrome - drug therapy ; Protein Binding ; Repetitive Sequences, Nucleic Acid - drug effects ; RNA - drug effects ; RNA Splicing ; Small Molecule Libraries ; Tremor - drug therapy</subject><ispartof>ACS chemical biology, 2012-10, Vol.7 (10), p.1711</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22948243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Disney, Matthew D</creatorcontrib><creatorcontrib>Liu, Biao</creatorcontrib><creatorcontrib>Yang, Wang-Yong</creatorcontrib><creatorcontrib>Sellier, Chantal</creatorcontrib><creatorcontrib>Tran, Tuan</creatorcontrib><creatorcontrib>Charlet-Berguerand, Nicolas</creatorcontrib><creatorcontrib>Childs-Disney, Jessica L</creatorcontrib><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><title>ACS chemical biology</title><addtitle>ACS Chem Biol</addtitle><description>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</description><subject>Animals</subject><subject>Ataxia - drug therapy</subject><subject>Binding, Competitive - drug effects</subject><subject>Cell Nucleus - drug effects</subject><subject>Cercopithecus aethiops</subject><subject>COS Cells</subject><subject>Fragile X Syndrome - drug therapy</subject><subject>Protein Binding</subject><subject>Repetitive Sequences, Nucleic Acid - drug effects</subject><subject>RNA - drug effects</subject><subject>RNA Splicing</subject><subject>Small Molecule Libraries</subject><subject>Tremor - drug therapy</subject><issn>1554-8937</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1j8FKAzEURYMgtlYX_oBk2S5Gk7ykM7MsRatQcKPgrrwkb9qRSWdIUmn_3oK6uptzDlzG7qR4kELJR2dBCAlmd8HG0hhdVDWUI3ad0pcQGuZVfcVGStW6UhrGLCx4Cth1PPQduUNHPO8w84xxSznxOF2uVrMpHYcZx73nbRhi_02Je2rInYF2z5uI2_YsfhaYUu9azOR5jhT6yDHjsUWeTnsf-0A37LLBLtHt307Yx_PT-_KlWL-tXpeLdTFINc-FNs47DaUjbEoyoJpKGgGkfO2l0hKh9PUc0VpTCQJZG0sWrFMSnDLoYcLuf7vDwQbymyG2AeNp8_8bfgAVb1h1</recordid><startdate>20121019</startdate><enddate>20121019</enddate><creator>Disney, Matthew D</creator><creator>Liu, Biao</creator><creator>Yang, Wang-Yong</creator><creator>Sellier, Chantal</creator><creator>Tran, Tuan</creator><creator>Charlet-Berguerand, Nicolas</creator><creator>Childs-Disney, Jessica L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20121019</creationdate><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><author>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Ataxia - drug therapy</topic><topic>Binding, Competitive - drug effects</topic><topic>Cell Nucleus - drug effects</topic><topic>Cercopithecus aethiops</topic><topic>COS Cells</topic><topic>Fragile X Syndrome - drug therapy</topic><topic>Protein Binding</topic><topic>Repetitive Sequences, Nucleic Acid - drug effects</topic><topic>RNA - drug effects</topic><topic>RNA Splicing</topic><topic>Small Molecule Libraries</topic><topic>Tremor - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Disney, Matthew D</creatorcontrib><creatorcontrib>Liu, Biao</creatorcontrib><creatorcontrib>Yang, Wang-Yong</creatorcontrib><creatorcontrib>Sellier, Chantal</creatorcontrib><creatorcontrib>Tran, Tuan</creatorcontrib><creatorcontrib>Charlet-Berguerand, Nicolas</creatorcontrib><creatorcontrib>Childs-Disney, Jessica L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>ACS chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Disney, Matthew D</au><au>Liu, Biao</au><au>Yang, Wang-Yong</au><au>Sellier, Chantal</au><au>Tran, Tuan</au><au>Charlet-Berguerand, Nicolas</au><au>Childs-Disney, Jessica L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</atitle><jtitle>ACS chemical biology</jtitle><addtitle>ACS Chem Biol</addtitle><date>2012-10-19</date><risdate>2012</risdate><volume>7</volume><issue>10</issue><spage>1711</spage><pages>1711-</pages><eissn>1554-8937</eissn><abstract>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</abstract><cop>United States</cop><pmid>22948243</pmid><doi>10.1021/cb300135h</doi></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1554-8937 |
ispartof | ACS chemical biology, 2012-10, Vol.7 (10), p.1711 |
issn | 1554-8937 |
language | eng |
recordid | cdi_pubmed_primary_22948243 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | Animals Ataxia - drug therapy Binding, Competitive - drug effects Cell Nucleus - drug effects Cercopithecus aethiops COS Cells Fragile X Syndrome - drug therapy Protein Binding Repetitive Sequences, Nucleic Acid - drug effects RNA - drug effects RNA Splicing Small Molecule Libraries Tremor - drug therapy |
title | A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T19%3A44%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20small%20molecule%20that%20targets%20r(CGG)(exp)%20and%20improves%20defects%20in%20fragile%20X-associated%20tremor%20ataxia%20syndrome&rft.jtitle=ACS%20chemical%20biology&rft.au=Disney,%20Matthew%20D&rft.date=2012-10-19&rft.volume=7&rft.issue=10&rft.spage=1711&rft.pages=1711-&rft.eissn=1554-8937&rft_id=info:doi/10.1021/cb300135h&rft_dat=%3Cpubmed%3E22948243%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22948243&rfr_iscdi=true |